abrdn plc Buys 188,871 Shares of Oculis Holding AG (NASDAQ:OCS)

abrdn plc lifted its stake in Oculis Holding AG (NASDAQ:OCS - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,009,424 shares of the company's stock after purchasing an additional 188,871 shares during the period. abrdn plc owned 2.49% of Oculis worth $17,150,000 as of its most recent SEC filing.

Analyst Ratings Changes

OCS has been the subject of several research analyst reports. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Oculis in a report on Monday, January 6th. Chardan Capital restated a "buy" rating and set a $28.00 price target on shares of Oculis in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis presently has a consensus rating of "Buy" and a consensus price target of $28.80.

Oculis Stock Down 1.4 %

Shares of OCS stock traded down $0.32 during trading hours on Monday, hitting $21.83. 55,539 shares of the company's stock traded hands, compared to its average volume of 110,834. Oculis Holding AG has a 12-month low of $10.55 and a 12-month high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $884.12 million, a price-to-earnings ratio of -11.31 and a beta of -0.24. The stock's fifty day simple moving average is $19.22 and its two-hundred day simple moving average is $15.53.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.